NeurologyLive® Friday 5 — June 2, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: World MS Day: Cognitive Function in Multiple Sclerosis

In recognition of World MS Day, Meghan Beier, PhD, MA, a health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine, discussed the effects of multiple sclerosis (MS) on cognitive function.

2: Peer Exchange: Challenges in Use of Generic DMTs for Treatment of MS

In episode 12 of this Peer Exchange series on "The Shifting Treatment Landscape of RRMS", experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.

3: NeuroVoices: Cornelia Drees, MD, on Understanding the Different Advantages of Microburst Vagus Nerve Stimulation

In the latest edition of our in-depth Q&A series, Cornelia Drees, MD, senior associate consultant, Department of Neurology, Mayo Clinic, discussed the potential of microburst vagus nerve stimulation as a more targeted treatment for drug-resistant epilepsy.

4: MS Misdiagnosis Is Still a Problem, But Promising Biomarkers May Be Part of the Solution

Andrew Solomon, MD, associate professor of neurological sciences and Chief of the Multiple Sclerosis Division at the University of Vermont in Burlington, discussed inherent biases affecting MS diagnosis and how advances in imaging may help curb diagnostic errors.

5: Role of Cholinergic Transcripts in Sex-Specific Declines of Alzheimer Disease: Hermona Seroq, PhD

The professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]